Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Majorczyk, Edyta ^a,b   Pawlik, Andrzej ^c   Gendosz, Daria ^a   Kuśnierczyk, Piotr ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b OPOLE UNIVERSITY OF TECHNOLOGY   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

KIR; KIR ligand; Methotrexate; Rheumatoid arthritis; Treatment response

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KIR2DS4 PROTEIN; METHOTREXATE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; KIR2DS4 PROTEIN, HUMAN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA C1 ANTIGEN; HLA C2 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS4;

ADULT; AGED; ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; GENETICS; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; BONE EROSION; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DISEASE DURATION; DNA ISOLATION; GENETIC ASSOCIATION; HAPLOTYPE; ONSET AGE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; FEMALE; GENOTYPE; HLA-C ANTIGENS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; RECEPTORS, KIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904770236     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-256     Document Type: Article

References (35)

1. Genetics of rheumatoid arthritis: an impressionist perspective. Jacob N, Jacob CO, Rheum Dis Clin North Am 2012 38 243 257
2. Role for innate immunity in rheumatoid arthritis. Falgarone G, Jaen O, Boissier MC, Joint Bone Spine 2005 72 17 25 (Pubitemid 40169959)
3. Regulatory NK cells in autoimmune response. Tian Z, Gershwin ME, Zhang C, J Autoimm 2012 39 206 215
4. Killer cell activating receptors function as costimulatory molecules on CD4 + CD28null T cells clonally expanded in rheumatoid arthritis. Namekawa T, Snyder MR, Yen J-H, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ, J Immunol 2000 165 1138 1145 (Pubitemid 30484786)
5. MHC class I molecules and KIRs in human history, health and survival. Parham P, Nat Rev Immunol 2005 5 201 214 (Pubitemid 40364822)
6. Human diversity of killer cell immunoglobulin-like receptors and disease. Rajalingam R, Korean J Hematol 2011 46 216 228
7. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Cooley S, Wesdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS, Blood 2010 116 2411 2419
8. Inhibitory receptors signal activation. Yokoyama WM, Immunity 2008 29 515 517
9. Regulation of the natural killer cell receptor repertoire. Raulet DH, Vance RE, McMahon CW, Annu Rev Immunol 2001 19 291 330 (Pubitemid 32368038)
10. Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Kuśnierczyk P, Front Immunol 2013 doi:10.3389/fimmu.2013.00008
11. The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLAB*27:09. Cauli A, Shaw J, Giles J, Hatano H, Rysnik O, Payeli S, McHugh K, Dessole G, Porru G, Desogus E, Fiedler S, Hölper S, Carette A, Blanco-Gelaz MA, Vacca A, Piga M, Ibba V, Garau P, La Nasa G, López-Larrea C, Mathieu A, Renner C, Bowness P, Kollnberger S, Rheumatology 2013 52 1952 1962
12. Pas de quatre: an interaction of HLA-B*2705 and KIR3DL2 homodimers in spondyloarthropathies. Kuśnierczyk P, Majorczyk E, Rheumatology 2013 52 1931 1932
13. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy. McGeough CM, Berrar D, Wright G, Mathews C, Gilmore P, Cunningham RT, Bjourson AJ, Rheumatol Int 2012 32 1647 1653
14. Going with the flow: methotrexate, adenosine, and blood flow. Cronstein BN, Ann Rheum Dis 2006 65 421 422
15. Are there differences in methotrexate kinetics between responding and nonresponding patients with rheumatoid arthritis? Capone D, Spanò A, Gentile A, Ferrara G, Itto E, Palmiero G, Basile V, Oriente P, BioDrugs 2000 13 373 379 (Pubitemid 30399449)
16. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S, Rheumatology (Oxford) 2003 42 1545 1549 (Pubitemid 37508930)
17. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J, Arthritis Rheum 2004 50 2766 2774 (Pubitemid 39209513)
18. Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Maillefert JF, Puéchal X, Falgarone G, Lizard G, Ornetti P, Solau E, Legré V, Lioté F, Sibilia J, Morel J, Maynadié M, Réseau Rhumato Study Group, Joint Bone Spine 2010 77 558 563
19. Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial. Aslibekyan S, Brown EE, Reynolds RJ, Redden DT, Morgan S, Baggott JE, Sha J, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Bridges SL Jr, Arnett DK, Pharmacogenomics J 2014 14 48 53
20. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W, Pharmacogenomics J 2013 13 227 234
21. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F, Arthritis Rheum 1993 3 729 740 (Pubitemid 23175613)
22. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Fuchs HA, Brooks RH, Callahan LF, Pincus T, Arthritis Rheum 1989 32 531 537 (Pubitemid 19146692)
23. Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wiśniewski A, Jasek M, Kuśnierczyk P, Genes Immun 2007 8 678 683 (Pubitemid 350238438)
24. DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. Frohn C, Schlenke P, Ebel B, Dannenberg C, Bein G, Kitchner H, J Immunol Meth 1998 218 155 160 (Pubitemid 28500142)
25. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Excoffier L, Slatkin M, Mol Biol Evol 1995 12 921 927
26. Characterization of CD4 + CD28null T cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis. Téo FH, de Oliveira RT, Mamoni RL, Ferreira MC, Nadruz W Jr, Coelho OR, Fernandes Jde L, Blotta MH, Cell Immunol 2013 281 11 19
27. CD4 + CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Niccoli G, Apa R, Lanzone A, Liuzzo G, Spaziani C, Sagnella F, Cosentino N, Moro F, Martinez D, Morciano A, Bacà M, Pazzano V, Gangale MF, Tropea A, Crea F, Fertil Steril 2011 95 2651 2654
28. The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis. Pinto-Medel MJ, García-León JA, Oliver-Martos B, López-Gómez C, Luque G, Arnáiz-Urrutia C, Orpez T, Marín-Bañasco C, Fernández O, Leyva L, J Neuroimmunol 2012 243 1 11
29. The expansion of CD4 + CD28- T cells in patients with rheumatoid arthritis. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, Gawrońska-Szklarz B, Arthritis Res Ther 2003 5 210 R213
30. Disease activity in patients with long-lasting rheumatoid arthritis is associated with changes in peripheral blood lymphocyte subpopulations. Smoleńska Z Pawłowska J, Daca A, Soroczyńska-Cybula M, Witkowski J, Bryl EM, Pol Arch Med Wewn 2012 122 591 598
31. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. van Bergen J, Thompson A, van der Slik A, Ottenhoff THM, Gussekloo J, Koning F, J Immunol 2004 173 6719 6726 (Pubitemid 39541057)
32. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, Goronzy JJ, J Exp Med 2001 193 1159 1167 (Pubitemid 32488368)
33. Killer immunoglobulin-like receptor (KIR) and HLA genotypes affect the outcome of allogeneic kidney transplantation. Nowak I, Magott-Procelewska M, Kowal A, Miazga M, Wagner M, Niepiekło-Miniewska W, Kamińska M, Wiśniewski A, Majorczyk E, Klinger M, Łuszczek W, Pawlik A, Płoski R, Barcz E, Senitzer D, Kuśnierczyk P, PLoS One 2012 7 44718
34. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AHW, Scand J Rheumatol 2006 35 124 127
35. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? Romão VC, Canhão H, Fonseca JE, BMC Medicine 2013 11 17